Sean Lavin

In a report published Thursday, BTIG Research analyst Sean Lavin initiated coverage on Hologic Inc. (NASDAQ: HOLX) with a Buy rating and $26.00 price target. Lavin noted four main reasons to buy this mid cap med tech company. The analyst first emphasized that earnings growth is "almost automatic...

In a report published Friday, BTIG Research analyst Sean Lavin initiated coverage on Allergan (NYSE: AGN) with a Buy rating and $115.00 price target. In the report, BTIG Research noted, “We are initiating coverage of Allergan Inc. (AGN) with a BUY rating and $115 price target based on 20x 12-24...